The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
The DNA sequence of human chromosome 22
Dunham, I., Hunt, A. R., Collins, J. E., Bruskiewich, R., Beare, D. M., Clamp, M., Smink, L. J., Ainscough, R., Almeida, J. P., Babbage, A., et al. (1999) · Nature · doi:10.1038/990031 · Cited by 1,157
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Crystal structure of human cytochrome P450 2C9 with bound warfarin
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinković, D., & Jhoti, H. (2003) · Nature · doi:10.1038/nature01862 · Cited by 821
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
Gonzalez, F. J., Skodat, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., & Meyer, U. A. (1988) · Nature · doi:10.1038/331442a0 · Cited by 715
Self-citationJohansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Self-citationPharmacogenetics and adverse drug reactions
Meyer, U. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03167-6 · Cited by 602
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Self-citationKimura, S., Umeno, M., Skoda, R. C., Meyer, U., & Gonzalez, F. J. (1989) · Europe PMC (PubMed Central) · Cited by 462
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
Heim, M., & Meyer, U. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)92086-w · Cited by 447
Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjöqvist, F., & Ingelman-Sundberg, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09721-4 · Cited by 430
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Self-citationAklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Schmid, B., Bircher, J., Preisig, R., & Küpfer, A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.235 · Cited by 383
Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.-M., Spire, C., Lafitte, J.-J., Meyer, U. A., & Broly, F. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00004 · Cited by 380
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Self-citationIdentification of the primary gene defect at the cytochrome P450 CYP2D locus
Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., & Wolf, C. R. (1990) · Nature · doi:10.1038/347773a0 · Cited by 330
Self-citationDistlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., & Sjöqvist, F. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10669-1 · Cited by 313
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
The DNA sequence of human chromosome 7
Hillier, L. W., Fulton, R. S., Fulton, L. A., Graves, T. A., Pepin, K. H., Wagner-McPherson, C., Layman, D., Maas, J., Jaeger, S., Walker, R., et al. (2003) · Nature · doi:10.1038/nature01782 · Cited by 285
Griese, E.-U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., M??rike, K., St??ven, T., & Eichelbaum, M. (1998) · Pharmacogenetics · doi:10.1097/00008571-199802000-00003 · Cited by 283
Self-citationClinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and Response
Lennard, M. S., Silas, J. H., Freestone, S., Ramsay, L. E., Tucker, G. T., & Woods, H. F. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212163072505 · Cited by 279
Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M. F., & Meyer, U. (1991) · Europe PMC (PubMed Central) · Cited by 274
Self-citationComprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
Zanger, U. M., Fischer, J., Raimundo, S., Stüven, T., Evert, B. O., Schwab, M., & Eichelbaum, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00004 · Cited by 266
Self-citationKagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., & Meyer, U. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44890-3 · Cited by 265
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.-B., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.
Zanger, U. M., Hauri, H. P., Loeper, J., Homberg, J. C., & Meyer, U. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.21.8256 · Cited by 238
Self-citationDopamine Formation from Tyramine by CYP2D6
Hiroi, T., Imaoka, S., & Funae, Y. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9232 · Cited by 237
ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE
Barbeau, A., Roy, M., Paris, S., Cloutier, T., Plasse, L., & Poirier, J. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90743-3 · Cited by 229
Chou, W. H., Yan, F.-X., de Leon, J., Barnhill, J., Rogers, T., Cronin, M., Pho, M., Xiao, V., Ryder, T. B., Liu, W. W., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00019 · Cited by 226
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., & Ingelman-Sundberg, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92546-6 · Cited by 223
The relationship between paroxetine and the sparteine oxidation polymorphism
Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.23 · Cited by 205
Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
McLellan, R. A., Oscarson, M., Seidega??rd, J., Price Evans, D. A., & Ingelman-Sundberg, M. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00003 · Cited by 204
Brockmöller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Müller‐Oerlinghausen, B., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127494 · Cited by 204
Bock, K. W., Schrenk, D., Forster, A., Griese, E.-U., M??rike, K., Brockmeier, D., & Eichelbaum, M. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00005 · Cited by 199
Self-citationSkoda, R. C., Gonzalez, F. J., Demierre, A., & Meyer, U. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5240 · Cited by 195
Gene expression in distinct regions of the heart
Thum, T., & Borlak, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)99016-0 · Cited by 195
Løvlie, R., Daly, A. K., Molven, A., Idle, J. R., & Steen, V. M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00779-x · Cited by 192
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Self-citationCYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal, S. S., & Kupfer, D. (1997) · PubMed · Cited by 187
Gaedigk, A., Gotschall, R. R., Forbes, N. S., Simon, S. D., Kearns, G. L., & Leeder, J. S. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199912000-00002 · Cited by 181
Gonzalez, F. J., Vilbois, F., Hardwick, J. P., McBride, O. W., Nebert, D. W., Gelboin, H. V., & Meyer, U. (1988) · Genomics · doi:10.1016/0888-7543(88)90100-0 · Cited by 176
Wuttke, H., Rau, T., Heide, R., Bergmann, K., Böhm, M., Weil, J., Werner, D., & Eschenhagen, T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127111 · Cited by 175
Yamazaki, S., Sato, K., Suhara, K., Sakaguchi, M., Mihara, K., & Omura, T. (1993) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a124232 · Cited by 168
Dahl, M.-L. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu, A., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054066.98065.7b · Cited by 158
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain
Siegle, I., Fritz, P., Eckhardt, K., Zanger, U. M., & Eichelbaum, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00007 · Cited by 153
Self-citationCYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR
Schaeffeler, E., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2003) · Human Mutation · doi:10.1002/humu.10280 · Cited by 153
Self-citationColler, J. K., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Eichelbaum, M. F., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01614.x · Cited by 150
Self-citationRegional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics
Miksys, S. L., Rao, Y., Hoffmann, E. B., Mash, D. C., & Tyndale, R. F. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01069.x · Cited by 150
Chen, S., Chou, W.-H., Blouin, R. A., Mao, Z. L., Humphries, L. L., Meek, Q. C., Neill, J. R., Martin, W. L., Hays, L. R., & Wedlund, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90148-4 · Cited by 149
Lundqvist, E., Johansson, I., & Ingelman‐Sundberg, M. (1999) · Gene · doi:10.1016/s0378-1119(98)00567-8 · Cited by 147
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man
Zanger, U. M., Vilbois, F., Hardwick, J. P., & Meyer, U. (1988) · Biochemistry · doi:10.1021/bi00415a010 · Cited by 146
Self-citationYokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I., & Gonzalez, F. J. (1993) · Pharmacogenetics · doi:10.1097/00008571-199310000-00005 · Cited by 144
Shin, J., Soukhova, N. V., & Flockhart, D. A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15029-5 · Cited by 143
A Combination of Mutations in the CYP2D6*17(CYP2D6Z) Allele Causes Alterations in Enzyme Function
Oscarson, M., Hidestrand, M., Johansson, I., & Ingelman‐Sundberg, M. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.6.1034 · Cited by 141
Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment
Rau, T., Heide, R., Bergmann, K., Wuttke, H., Werner, U., Feifel, N., & Thomas Eschenhagen, A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00007 · Cited by 140
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
Steiner, E., Bertilsson, L., Säwe, J., Bertling, I., & Sjöqvist, F. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.176 · Cited by 133
Wolff, T., Distlerath, L. M., Worthington, M., Groopman, J. D., Hammons, G., Kadlubar, F. F., Prough, R. A., Martin, M. V., & Guengerich, F. P. (1985) · PubMed · Cited by 124
Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships
Chou, W.-H., Yan, F., Robbins‐Weilert, D., et al. (2003) · Clinical Chemistry · doi:10.1373/49.4.542 · Cited by 121
Daly, A. K., Steen, V. M., Fairbrother, K. S., & Idle, J. R. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)72024-4 · Cited by 118
PCR-based genotyping for duplicated and deleted CYP2D6 genes
Johansson, I., Lundqvist, E., Dahl, M., & Ingelman‐Sundberg, M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00008 · Cited by 114
CYP2D6 phenotype ??? genotype relationships in African-Americans and Caucasians in Los Angeles
Leathart, J. B. S., London, S. J., Steward, A., et al. (1998) · Pharmacogenetics · doi:10.1097/00008571-199812000-00010 · Cited by 114
Gilham, D. E., Cairns, W. J., Paine, M. J. I., Modi, S. P., Poulsom, R., Roberts, G. C. K., & Wolf, C. R. (1997) · Xenobiotica · doi:10.1080/004982597240802 · Cited by 113
Paine, M. J. I., McLaughlin, L. A., Flanagan, J. U., Kemp, C. A., Sutcliffe, M. J., Roberts, G. C. K., & Wolf, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209519200 · Cited by 112
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
Yu, A., Idle, J. R., Herraiz, T., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054094.48725.b7 · Cited by 111
Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U. M., & Meyer, U. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67305-3 · Cited by 111
Self-citationYu, A., Kneller, B. M., Rettie, A. E., & Haining, R. L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039891 · Cited by 105
Rostami‐Hodjegan, A., Lennard, M. S., Woods, H. F., & Tucker, G. T. (1998) · Pharmacogenetics · doi:10.1097/00008571-199806000-00005 · Cited by 104
Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputi, A. P., & Perucca, E. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050220 · Cited by 103
Løvlie, R., Daly, A. K., Matre, G. E., Molven, A., & Steen, V. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00006 · Cited by 101
Ellis, S. W., Hayhurst, G. P., Smith, G. C., Lightfoot, T. J., Wong, M. M. S., Simula, A. P., Ackland, M. J., Sternberg, M. J. E., Lennard, M. S., Tucker, G. T., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29055 · Cited by 96
Dahl, M., Yue, Q., Roh, H., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199506000-00004 · Cited by 95
Evans, W. E., Relling, M. V., Petros, W. P., Meyer, W. H., Mirro, J., & Crom, W. R. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.74 · Cited by 95
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror
Baumann, P., & Rochat, B. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503001-00004 · Cited by 92
Kroemer, H. K., Mikus, G., Kronbach, T., Meyer, U., & Eichelbaum, M. F. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.5 · Cited by 86
Self-citationMadani, S., Paine, M. F., Lewis, L., Thummel, K. E., & Shen, D. D. (1999) · Pharmaceutical Research · doi:10.1023/a:1018989211864 · Cited by 85
Fukuda, T., Nishida, Y., Imaoka, S., Hiroi, T., Naohara, M., Funae, Y., & Azuma, J. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1936 · Cited by 82
Cytochrome P-450 activities in human and rat brain microsomes
Voirol, P., Jonzier-Perey, M., Porchet, F., Reymond, M. J., Janzer, R. C., Bouras, C., Strobel, H. W., Kosel, M., Eap, C. B., & Baumann, P. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02354-9 · Cited by 79
Vandel, S. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80088-3 · Cited by 75
Steen, V. M., Molven, A., Aarskog, N. K., et al. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2251 · Cited by 75
Griese, E., Ilett, K. F., Kitteringham, N. R., Eichelbaum, M. F., Powell, H., Spargo, R. M., Souëf, P. N. L., Musk, A. W., & Minchin, R. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00008 · Cited by 71
Self-citationPolymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.
Jackson, P., Tucker, G., Lennard, M., & Woods, H. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb02933.x · Cited by 66
Bathum, L., Johansson, I., Ingelman‐Sundberg, M., rder, M. H., & sen, K. B. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00004 · Cited by 65
Kahn, G. C., Boobis, A. R., Murray, S., Brodie, M. J., & Davies, D. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01430.x · Cited by 64
Daly, A. K., Idle, J. R., Fairbrother, K. S., Andreassen, O. A., London, S. J., & Steen, V. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00005 · Cited by 58
Murphy, G. M., Pollock, B. G., Kirshner, M. A., Pascoe, N., Cheuk, W., Mulsant, B. H., & Reynolds, C. F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00289-5 · Cited by 57
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans
Eichelbaum, M. F., & Woolhouse, N. M. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00635712 · Cited by 45
Self-citationChristensen, P. M., Gøtzsche, P. C., & Brøsen, K. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050219 · Cited by 45
Christensen, P. M., Gøtzsche, P. C., & sen, K. B. (1998) · Pharmacogenetics · doi:10.1097/00008571-199812000-00003 · Cited by 37
Evert, B. O., Eichelbaum, M., Haubruck, H., & Zanger, U. M. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00004948 · Cited by 37
Self-citation(+)-Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver
Prueksaritanont, T., Dwyer, L. M., & Cribb, A. E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02052-7 · Cited by 33
Endrizzi, K., Fischer, J., Klein, K., Schwab, M. G., Nussler, A. K., Neuhaus, P., Eichelbaum, M. F., & Zanger, U. M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5453 · Cited by 26
Self-citationGene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Mt, L., Ceroni, M., Martignoni, E., Bertazzi, P. A., Caporaso, N. E., & Nappi, G. (1996) · PubMed · Cited by 18
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“The molecular studies that followed were reviewed previously (Meyer & Zanger, 1997; Zanger et al., 2004; Ingelman-Sundberg, 2005).”
BackgroundSelf-citationIngelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Metadata
- Authors
- Zanger, U. M., Raimundo, S., & Eichelbaum, M.
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2004-01-01
- Volume
- 369
- Issue
- 1
- Pages
- 23-37
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W2008825099
- Cited by
- 795
- References
- 100
- FWCI
- 36.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.